{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Consolidation+Therapy&page=3", "query": { "intervention": "Consolidation Therapy", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 730, "total_pages": 73, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Consolidation+Therapy&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Consolidation+Therapy&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T23:28:32.111Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00061945", "title": "Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Undifferentiated Leukemia", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "L1 Adult Acute Lymphoblastic Leukemia", "L1 Childhood Acute Lymphoblastic Leukemia", "L2 Adult Acute Lymphoblastic Leukemia", "L2 Childhood Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "allopurinol", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "trimethoprim-sulfamethoxazole", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "acyclovir", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 302, "start_date": "2003-06", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2022-05-03", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061945" }, { "nct_id": "NCT01859819", "title": "Treatment for Advanced B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large Cell Lymphoma", "Burkitt's Lymphoma", "High Grade B-cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "IT Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "31 Years", "sex": "ALL", "summary": "3 Years to 31 Years" }, "enrollment_count": 45, "start_date": "2013-01", "completion_date": "2021-06", "has_results": false, "last_update_posted_date": "2022-10-25", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 5, "location_summary": "Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Valhalla", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859819" }, { "nct_id": "NCT07130695", "title": "Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Olutasidenib Investigational Agent Administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-02-02", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07130695" }, { "nct_id": "NCT00002912", "title": "Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "valspodar", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3, "start_date": "1997-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 50, "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 39 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002912" }, { "nct_id": "NCT00476047", "title": "Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoid Leukemia in Remission", "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage III Small Lymphocytic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Tositumomab and Iodine I 131 Tositumomab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2007-02", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-10-12", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00476047" }, { "nct_id": "NCT00673738", "title": "Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Conformal Thoracic Radiotherapy (CTRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2008-04", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2015-10-08", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00673738" }, { "nct_id": "NCT07504458", "title": "Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Promyelocytic Leukemia (APL)", "Acute Promyelocytic Leukaemia", "Acute Promyelocytic Leukemia With PML-RARA", "Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA", "Acute Promyelocytic Leukemia" ], "interventions": [ { "name": "QTX-2101 + ATRA", "type": "DRUG" }, { "name": "IV arsenic trioxide (ATO) + ATRA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Quetzal Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "71 Years", "sex": "ALL", "summary": "18 Years to 71 Years" }, "enrollment_count": 150, "start_date": "2026-06-08", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07504458" }, { "nct_id": "NCT02573363", "title": "Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 25, "start_date": "2015-10-07", "completion_date": "2019-05-03", "has_results": false, "last_update_posted_date": "2020-04-08", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02573363" }, { "nct_id": "NCT03404193", "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Chronic Myelomonocytic Leukemia", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome", "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2018-01-18", "completion_date": "2026-03-05", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03404193" }, { "nct_id": "NCT00777829", "title": "Memory Consolidation in Pharmacologically Enhanced Naps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sleep" ], "interventions": [ { "name": "zolpidem", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 30, "start_date": "2008-09-01", "completion_date": "2011-06-01", "has_results": true, "last_update_posted_date": "2021-07-28", "last_synced_at": "2026-10-03T23:28:32.111Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777829" } ] }